Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. Galsky MD, Valderrama BP, Maruzzo M, Font A, et al. N Engl J Med 2026;395:338-348.

Read + Share

Amedeo Smart

Independent Medical Education

Galsky MD, Valderrama BP, Maruzzo M, Font A, et al. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med 2026;395:338-348.
PMID: 42485627